NCT04949191: The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 90 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients currently enrolled and receiving treatment in an Incyte-sponsored clinical study (parent protocol of pemigatinib) as monotherapy or combination therapy
Exclusions: Patients with evidence of progressive disease

Comments are closed.

Up ↑